Mode
Text Size
Log in / Sign up
N/A N=418

Observational Study of OCT in a Patients Undergoing FFR

Coronary Artery Disease

Enrolled (actual)
418
Serious AEs
26.8%
Results posted
Jul 2020
Primary outcome: Primary: Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting — 0; 6.7; 6.2; 0.2 Percentage of per-subject incidence

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
OCT stent guidance (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Abbott Medical Devices
Primary completion
Mar 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting
0; 7.2; 6.7; 0.7; 0.2; 7.9
PRIMARY
Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting
0; 7.2; 6.7; 0.7; 0.2; 7.9
PRIMARY
Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting (Academic Research Consortium(ARC))
0; 8.3; 7.8; 2.5; 1.8; 9.3
SECONDARY
Percentage of Change in Physician Decision-making Pre and Post PCI Due to OCT
57; 27; 65; 65

Summary

The purpose of this study is to define and evaluate optical coherence tomography (OCT) stent guidance parameters through prospective data collection in percutaneous coronary intervention (PCI) procedures of de novo lesions.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years.
  • Patient provides signed written informed consent before any study-specific procedure.
  • De novo coronary artery disease in target vessel.
  • Single or multi vessel disease. For multi vessel disease up to two vessels and three lesions treated, with no more than two lesions per vessel. Vessel is defined as, left anterior descending, left circumflex, and right coronary arteries. Any branch within the vessel is considered part of the vessel.
  • Elective or ad hoc PCI, stable angina, acute coronary syndrome (unstable angina and NSTEMI).
  • Angiographically significant (>50% visual estimation) stenosis present in at least one native coronary artery.
  • Mandatory use of FFR and OCT pre and post PCI. PCI strongly recommended in subjects with an FFR ≤ 0.80 in target vessel.

Exclusion Criteria

  • Subjects with STEMI, emergent PCI, or in cardiogenic shock.
  • Subjects with target left main lesion.
  • Subjects with restenosis or stent thrombosis in the target vessel.
  • Planned use of bare metal stent.
  • Known renal insufficiency (examples being but not limited to eGFR 90°) or excessive tortuosity (> two 45° angles) proximal to or within the target lesion.
  • Vessel(s) and lesion(s) not amenable for PCI, for example diffuse disease.
  • Any other medical condition that in the opinion of the investigator will interfere with patient safety or study results.
  • Currently participating in another clinical study that interferes with study results.
  • Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure.
  • Life expectancy less than 1 year.
  • Potential for non-compliance to protocol requirements and follow-up.
  • Planned or prior heart transplantation or listed for heart transplant.
  • Any condition that precludes the subject from undergoing PCI, for example subjects with heparin induced thrombocytopenia, or contrast allergy.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01663896). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search